B-MICS better than C-SICS

Article

Biaxial microincision cataract surgery (B-MICS) is more successful than traditional cataract surgery in improving optical performance and reducing higher order aberrations, according to study results published in the December issue of the British Journal of Ophthalmology.

Biaxial microincision cataract surgery (B-MICS) is more successful than traditional cataract surgery in improving optical performance and reducing higher order aberrations, according to study results published in the December issue of the British Journal of Ophthalmology.

Professor PJ Pisella of the department of ophthalmology at the University Hospital of Bretonneau in Tours, France treated patients with bilateral cataract with B-MICS through a 1.7 mm clear corneal incision in one eye, and coaxial small-incision cataract surgery (C-SICS) through a 2.8 mm clear corneal incision in the opposite eye. All eyes were implanted with the Akreos MI60 AO intraocular lens (Bausch & Lomb), and the team compared corneal and ocular aberrations pre- and three-months postoperatively.

At the three-month follow-up point, eyes treated with B-MICS had lower values and reduced instances of trefoil, trefoil-like, higher-order aberrations, and corneal root mean square (RMS) when compared with C-SICS-treated eyes, although there were no differences between the two groups in terms of refraction, astigmatism and visual acuity values.

Thus the researchers concluded that B-MICS is a better surgical option than C-SICS for treating eyes with cataract, as it appears to reduce corneal aberrations and does not compromise postoperative optical performance.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.